Press releases

Pharmacy

News and trends in cancer research

20 August, 2014 - Karolinska Institutet

Some twenty of the world’s leading cancer researchers will participate in a conference at Karolinska Institutet. Their presentations will be alternated with the latest news from Swedish cancer research. Everything from tumour biology to drug development and health service implementation, within all cancer areas.

Dismisses link between suicidal behaviour and ADHD drugs

18 June, 2014 - Karolinska Institutet

[PRESS RELEASE 18/6/2014] A new register-based study from Karolinska Institutet in Sweden shows that drug therapy for ADHD does not entail an increased risk of suicide attempts or suicide, as was previously feared. The results are published in the British Medical Journal (BMJ).

New general concept for the treatment of cancer

3 April, 2014 - Karolinska Institutet

[PRESS RELEASE 3/4/2014] A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells

New cellular mechanism represses immune reaction in type I-diabetes

10 March, 2014 - Karolinska Institutet

[PRESS RELEASE 10/3/2014] Direct contact between different types of immune cells protects tissues from being attacked by the immune defence, according to a new study by researchers from Karolinska Institutet and University of Miami Miller School of Medicine. The findings, published in the Journal of Experimental Medicine, increase the knowledge of type I diabetes and other disorders caused by harmful immune reactions and may ultimately lead to therapies that regenerate the damaged tissue.

New discovery solves problem of anti-inflammatory substance

4 March, 2014 - Karolinska Institutet

There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body’s inflammatory response. However, in clinical trials, such molecules have proven to be only moderately effective. Now, researchers at Karolinska Institutet have successfully refined their understanding of why previous substances have been less effective – and in so doing have produced a molecule that gets around the problem.

Early atherosclerotic plaques regress when cholesterol levels are lowered

28 February, 2014 - Karolinska Institutet

Early but not advanced forms of atherosclerotic plaques in the vessel wall disappear when the levels of ‘bad’ cholesterol are lowered, according to a study in mice from Karolinska Institutet, Sweden. The findings, published in PLoS Genetics, indicate that preventative cholesterol-lowering treatment could prevent more advanced, clinically relevant plaque to develop.

New discovery paves the way for medicine for people with hearing disabilities

27 February, 2014 - Karolinska Institutet

[PRESS RELEASE 27/2/2014] Researchers at Karolinska Institutet in Sweden have identified a biological circadian clock in the hearing organ, the cochlea. This circadian clock controls how well hearing damage may heal and opens up a new way of treating people with hearing disabilities.

Impaired recovery from inflammation linked to Alzheimer’s

14 February, 2014 - Karolinska Institutet

[PRESS RELEASE 14/01/2014] New research from Karolinska Institutet in Sweden shows that the final stage of the normal inflammatory process may be disrupted in patients with Alzheimer’s disease. A study published in the journal Alzheimer’s & Dementia shows that levels in the brain and cerebrospinal fluid of the molecules necessary for tissue recovery through the clearance of harmful inflammatory substances are lower than normal in patients with Alzheimer’s disease. The study also showed association between the lower levels of these molecules with impaired memory function.

Brittle-bone babies helped by fetal stem cell grafts

16 December, 2013 - Karolinska Institutet

[PRESS RELEASE 16 DECEMBER 2013] Osteogeneis imperfecta (OI) is a congenital bone disease that causes stunted growth and repeated, painful fracturing. Ultrasound scans can reveal fractures already in the fetus, and now an international team of researchers from Sweden, Singapore and Taiwan have treated two babies in utero by injecting bone-forming stem cells. The longitudinal results of the treatment are published in Stem Cells Translational Medicine.

Promising results for Swedish cancer drug candidate

6 December, 2013 - Karolinska Institutet

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.